Showing 6751-6760 of 8842 results for "".
- Organon to Acquire VTAMA Maker Dermavanthttps://practicaldermatology.com/news/organon-acquire-vtama-maker-dermavant/2468226/Organon and Dermavant Sciences Ltd. announced that they have entered into a definitive agreement, under which Organon will acquire Dermavant, a Roivant company whose product VTAMA® (tapinarof) cream, 1%, for the topical treatment of mild, moderate, and severe plaque psoriasis in adults was approv
- Tralokinumab-ldrm 300 mg/2 mL Single-Dose Autoinjector Available in UShttps://practicaldermatology.com/news/tralokinumab-ldrm-300-mg2-ml-single-dose-autoinjector-available-us/2468195/The Adbry® (tralokinumab-ldrm) 300 mg/2 mL single-dose autoinjector is now available in the United States for patients 12 and older with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisab
- ASDS Hosts New 'Expertise Summit'https://practicaldermatology.com/news/asds-hosts-new-expertise-summit/2468191/More than 50 dermatologic surgeons and dermatology residents gathered in Chicago, Illinois, on September 7-8 for a new course from the American Society for Dermatologic Surgery (ASDS), titled “ASDS Expertise Summit: Surgery. Injectables.” Practical Dermatology Editorial Board member Dr. As
- Lebrikizumab Gains FDA Approval for ADhttps://practicaldermatology.com/news/lebrikizumab-gains-fda-approval-ad/2468189/The targeted IL-13 inhibitor lebrikizumab was approved by the US Food and Drug Administration for the treatment of adults and children 12 and older who weigh at least 88 lbs with moderate-to-severe atopic dermatitis that is not well controlled despite treatment with topical prescription therapies
- IGSRT Shows High Recurrence-Free Rates in Non-Melanoma Skin Cancerhttps://practicaldermatology.com/news/igsrt-shows-high-recurrence-free-rates-non-melanoma-skin-cancer/2468185/Nonmelanoma skin cancer (NMSC) treated with Image-Guided Superficial Radiation Therapy (IGSRT) showed consistently high freedom from recurrence rates, regardless of patient age or sex, according to a new analysis. The large retrospective cohort study, published in Geriatrics and c
- Lebrikizumab Shows Significant Improvement in Atopic Dermatitishttps://practicaldermatology.com/news/lebrikizumab-shows-significant-improvement-atopic-dermatitis/2468116/Lebrikizumab monotherapy showed significant improvements in clinical signs, symptoms, and quality of life in patients with moderate-to-severe atopic dermatitis over 16 weeks, according to new research. The analysis of two phase 3 placebo-controlled studies (ADvocate1 and ADvocate2) looked
- Age-related Fibroblast Changes Drive Melanoma in Males, Study Sayshttps://practicaldermatology.com/news/age-related-fibroblast-changes-drive-melanoma-males-study-says/2468115/Age-related changes in fibroblasts contribute to development of aggressive, treatment-resistant melanoma in males, according to a Johns Hopkins Kimmel Cancer Center study published in Cell. The authors of the study, Dr. Ashani Weeraratna and colleagues, had previously shown in studies that
- Study: Melanoma Declining Among Ages 30-59 in Swedenhttps://practicaldermatology.com/news/study-melanoma-declining-among-ages-30-59-sweden/2468114/Melanoma incidence and mortality rates have declined in recent years among 30- to 59-year-olds in Sweden, according to a recent study published in JAMA Dermatology. A cohort study involving Sweden’s entire population found a continuous rise in primary invasive cutaneous melanoma incidence
- Report: Global Skin Cancer Treatment Market to Hit $14.5 Billion by 2031https://practicaldermatology.com/news/global-skin-cancer-treatment-market-poised-rapid-growth-expected-hit-145-billion-2031/2468065/A recent report from Allied Analytics said the global skin cancer treatment market is projected to nearly double, reaching $14.5 billion by 2031, driven by an increasing incidence of skin cancer and advancements in treatment options. The $7.2 billion (2021) treatment market, according to t
- Analysis Shows High Incidence of Skin Eruptions with Tebentafusp in Uveal Melanomahttps://practicaldermatology.com/news/high-incidence-skin-eruptions-tebentafusp-uveal-melanoma/2468062/Tebentafusp-associated skin toxicity was prevalent in patients treated for metastatic uveal melanoma, a recent study reported. Study researchers looked at a cohort study of 33 patients treated with tebentafusp and identified skin symptoms in 26 patients (median follow-up of 21.5 months for